Recent actions by the FDA and NIH in response to the current political climate have left key stakeholders in clinical trials ...
Sepehr Shojaei, VP of Design Solutions at Lightship, talks about how the company works with pharma and contract research ...
The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback